Lexaria Bioscience Corp (LEXX)

[Shawking]

“As we look towards 2022 and 2023, Lexaria is also taking steps to ensure we have multiple choices in how we fund the Company. Some details must remain undisclosed for now and will be revealed at the appropriate times, but in other respects we clearly are trying to position the Company for non-dilutive injections of capital through strategic partners and other commercial relationships.”
"Lexaria is also in discussions with a number of larger companies in Europe and North America regarding licensed use of our DehydraTECH technology both for consumer sectors as well as – for the first time ever - within the pharmaceutical industry."
Lexaria is still waiting on at least 2 more reports on the secondary aims of the hypertension study HYPER-H21-4. Clinicians are writing peer reviewed papers, which would be published, so one can assume that the results were positive. Secondary aims were arterial stiffness, vascular health biomarkers, inflammation, heart rate variability, and the psychological well-being of patients. Take your pick. A deal with a pharmaceutical company could come after all the data is published.